Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Small-Molecule Inhibitors of Angiogenesis

Posted Jun 15 2010 5:00pm

Description of Invention:
Angiogenesis, the growth of new blood vessels from existing vessels, is a normal and vital process in growth and development. Deregulation of angiogenesis plays a role in many human diseases, including cancer, age-related macular degeneration, diabetic retinopathy, and endometriosis.

NCI investigators have used a cell-based high-throughput screening method to identify a set of anti-angiogenic small molecules. These compounds are highly active, inhibiting both endothelial cell growth and tube formation, and are not cytotoxic. Structure-activity relationship analysis has revealed that these compounds are unrelated to known anti-angiogenic compounds, and hence may operate through a novel mechanism of action. Thus, these compounds would be promising candidates for the development of new anti-angiogenesis therapeutics.

Applications:
Development of new anti-angiogenesis therapeutics.

Advantages:
These compounds are structurally unrelated to other known anti-angiogenesis compounds, and exhibit high activity without cytotoxicity.

Development Status:
In vivo studies using xenograft models are underway.

Inventors:
Enrique Zudaire Ubani (NCI)


Patent Status:
HHS, Reference No. E-263-2009/0
US, Application No. 61/230,667 filed 31 Jul 2009


Related Technologies:
US, Application No. 12/060,752 filed 01 Apr 2008, Reference No. E-281-2007/0
US, Application No. 60/976,732 filed 01 Oct 2007, Reference No. E-281-2007/0


Relevant Publication:
  1. In preparation.


Licensing Status:
Available for licensing.

Collaborative Research Opportunity:
The National Cancer Institute Angiogenesis Core Facility is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize a new set of non-cytotoxic antiangiogenic small molecules. Please contact John D. Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more information. Click here to view the NCI collaborative opportunity announcement.


Portfolios:
Cancer
Cancer - Therapeutics
Internal Medicine
Internal Medicine - Therapeutics
In-vivo Data



For Additional Information Please Contact:
Tara Kirby Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: tk200h@nih.gov
Phone: 301-435-4426
Fax: 301-402-0220


Ref No: 2045

Updated: 06/2010

Post a comment
Write a comment:

Related Searches